Sarepta Announces Completion of ESSENCE Trial for Exon 45 & 53 Skipping Therapies
Sarepta Therapeutics has announced top-line results from the ESSENCE trial, a global, randomized double-blind, placebo-controlled Phase 3 confirmatory study evaluating the efficacy and safety of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) in individuals living…Learn More


